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Abstract: Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current
coronavirus disease 19 (COVID-19) pandemic. Protease inhibitors are under consideration as
virus entry inhibitors that prevent the cleavage of the coronavirus spike (S) protein by cellular
proteases. Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor
SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable
concentrations. An analysis of proteomics and translatome data indicated that SARS-CoV-2 replication
is associated with a downregulation of host cell protease inhibitors. Hence, aprotinin may compensate
for downregulated host cell proteases during later virus replication cycles. Aprotinin displayed
anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell
air–liquid interface cultures) and against four virus isolates. In conclusion, therapeutic aprotinin
concentrations exert anti-SARS-CoV-2 activity. An approved aprotinin aerosol may have potential for
the early local control of SARS-CoV-2 replication and the prevention of COVID-19 progression to a
severe, systemic disease.
Keywords: severe acute respiratory syndrome coronavirus; severe acute respiratory syndrome
coronavirus 2; 2019-nCoV; COVID-19; antiviral; drug discovery; aprotinin
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1. Introduction
Severe acute respiratory syndrome virus 2 (SARS-CoV-2), a novel betacoronavirus, causes a
respiratory disease and pneumonia called coronavirus disease 19 (COVID-19) and is the cause of
a current pandemic responsible for millions of cases and hundreds of thousands of deaths [1–7].
Drugs for the treatment of COVID-19 are urgently needed.
Cell entry of coronaviruses is mediated by the interaction of the viral spike (S) protein with
their host cell receptors, which differ between different coronaviruses [8]. For example, Middle East
respiratory syndrome coronavirus (MERS-CoV) uses dipeptidyl peptidase 4 (DPP4) as a cellular
receptor [8]. Host cell entry of SARS-CoV-2 and of the closely related severe acute respiratory syndrome
virus (SARS-CoV) is mediated by angiotensin-converting enzyme 2 (ACE2) [8–10]. S binding to
ACE2 depends on S cleavage at three sites (S1, S2, and S2’) by host cell proteases, typically by the
transmembrane serine protease 2 (TMPRSS2), and can be inhibited by serine protease inhibitors [9,10].
Camostat was the first serine protease inhibitor that was shown to inhibit TMPRSS2 [9]. Subsequently,
additional TMPRSS2 inhibitors, including nafamostat and Arbidol derivatives, were demonstrated to
interfere with SARS-CoV-2 internalization into host cells [11–13].
Aprotinin is a serine protease inhibitor, which has previously been shown to inhibit TMPRSS2
and has been suggested as a treatment option for influenza viruses and coronaviruses [14,15].
Herein, we investigated the effects of aprotinin against SARS-CoV-2.
2. Materials and Methods
2.1. Drugs
SERPINA1/alpha-1 antitrypsin (Prolastin) was obtained from Grifols (Barcelona, Spain).
Aprotinin was purchased from Sigma-Aldrich (Darmstadt, Germany)).
2.2. Cell Culture
The Caco2 cell line was obtained from DSMZ (Braunschweig, Germany), and Calu-3 from ATCC
(Manassas, VA, US). The cells were grown at 37 ◦C in minimal essential medium (MEM) supplemented
with 10% fetal bovine serum (FBS), 100 IU/mL of penicillin, and 100 µg/mL of streptomycin. All culture
reagents were purchased from Sigma-Aldrich. Cells were regularly authenticated by short tandem
repeat (STR) analysis and tested for mycoplasma contamination.
Lung tissue for the isolation of primary epithelial cells was provided by the Hannover Medical
School, Institute of Pathology (Hannover, Germany). The use of tissue was approved by the ethics
committee of the Hannover Medical School (MHH, Hannover, Germany, number 2701–2015) and was
in compliance with The Code of Ethics of the World Medical Association. Primary bronchial epithelial
cells were isolated from the lung explant tissue of a patient with lung emphysema as described
previously [16]. All patients or their next of kin gave written informed consent for the use of their lung
tissue for research. Basal cells were expanded in Keratinocyte-SFM medium supplemented with bovine
pituitary extract (25 µg/mL), human recombinant epidermal growth factor (0.2 ng/mL, all from Gibco,
Schwerte, Germany), isoproterenol (1 nM, Sigma), Antibiotic/Antimycotic Solution (Sigma-Aldrich),
and MycoZap Plus PR (Lonza, Cologne, Germany) and cryopreserved until further use.
For differentiation, the cells were thawed and passaged once in PneumaCult-Ex Medium
(StemCell Technologies, Cologne, Germany) and then seeded on transwell inserts (12-well plate, Sarstedt,
Nümbrecht, Germany) at 4 × 104 cells/insert. Once the cell layers reached confluency, the medium on
the apical side of the transwell was removed, and medium in the basal chamber was replaced with
PneumaCult ALI Maintenance Medium (StemCell Technologies), including Antibiotic/Antimycotic
Solution (Sigma-Aldrich) and MycoZap Plus PR (Lonza). During a period of four weeks, the medium
was changed and the cell layers were washed with PBS every other day. Criteria for successful
differentiation were the development of ciliated cells and ciliary movement, an increase in transepithelial
electric resistance indicative of the formation of tight junctions, and mucus production.
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2.3. Virus Infection
The isolates SARS-CoV-2/1/Human/2020/Frankfurt (SARS-CoV-2/FFM1), SARS-CoV-2/2/Human/
2020/Frankfurt (SARS-CoV-2/FFM2), SARS-CoV-2/6/Human/2020/Frankfurt (SARS-CoV-2/FFM6),
and SARS-CoV-2/7/Human/2020/Frankfurt (SARS-CoV-2/FFM7) were isolated and cultivated in Caco2
cells as previously described [17,18]. Virus titers were determined as TCID50/mL in confluent cells in
96-well microtiter plates [19,20].
2.4. Antiviral Assay
Confluent cell cultures were infected with SARS-CoV-2 in 96-well plates at a multiplicity of
infection (MOI) of 0.01 in the absence or presence of the drug. The cytopathogenic effect (CPE) was
assessed visually 48 h post-infection [19]. Concentrations that inhibited CPE formation by 50% (IC50)
were determined using CalcuSyn (Biosoft, Cambridge, UK).
2.5. Viability Assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay modified after Mosman [21], as previously described [22]. Confluent cell cultures in
96-well plates were incubated with the drug for 48 h. Then, 25 µL of MTT solution (2 mg/mL (w/v) in
PBS) were added per well, and the plates were incubated at 37 ◦C for an additional 4 h. After this,
the cells were lysed using 200 µL of a buffer containing 20% (w/v) sodium dodecylsulfate and 50% (v/v)
N,N-dimethylformamide with the pH adjusted to 4.7 at 37 ◦C for 4 h. Absorbance was determined at
570 nm for each well using a 96-well multiscanner (Tecan, Crailsheim, Germany). After subtracting of
the background absorption, the results are expressed as percentage viability relative to control cultures
that received no drug. Drug concentrations that inhibited cell viability by 50% (CC50) were determined
using CalcuSyn (Biosoft).
2.6. Immunostaining for SARS-CoV-2 S Protein
Immunostaining was performed as previously described [23], using a monoclonal antibody
directed against SARS-CoV-2 S protein (1:1500 dilution, Sino Biological, Eschborn, Germany)
24 h post-infection.
2.7. Caspase 3/7 Activation
Caspase 3/7 activation was determined using the Caspase-Glo® 3/7 Assay
(Promega, Walldorf, Germany) according to the manufacturer’s instructions.
2.8. qPCR
SARS-CoV-2 RNA from the cell culture supernatant samples was isolated using AVL buffer
and the QIAamp Viral RNA Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Absorbance-based quantification of the RNA yield was performed using the Genesys
10S UV-Vis Spectrophotometer (Thermo Fisher Scientific, Dreieich, Germany). RNA was subjected
to OneStep qRT-PCR analysis using the Luna Universal One-Step RT-qPCR Kit (New England
Biolabs, Frankfurt am Main, Germany) and a CFX96 Real-Time System, C1000 Touch Thermal Cycler
(Bio-Rad, Feldkirchen, Germany). Primers were adapted from the WHO protocol29 targeting the open
reading frame for RNA-dependent RNA polymerase (RdRp): RdRP_SARSr-F2 (GTG ARA TGG TCA
TGT GTG GCG G) and RdRP_SARSr-R1 (CAR ATG TTA AAS ACA CTA TTA GCA TA) using 0.4 µM
per reaction. Standard curves were created using plasmid DNA (pEX-A128-RdRP) harboring the
corresponding amplicon regions for RdRp target sequence according to GenBank Accession number
NC_045512. For each condition, three biological replicates were used. The mean and standard deviation
were calculated for each group.
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2.9. Western Blot
Cells were lysed using Triton-X-100 sample buffer (Sigma-Aldrich), and proteins were
separated by SDS-PAGE. Detection occurred by using specific antibodies against SARS-CoV-2 N
(1:1000 dilution, SARS-CoV-2 Nucleocapsid Antibody, Rabbit monoclonal antibody (Mab), #40143-R019,
Sino Biological), ACE2 (1:500 dilution, Anti-ACE2 antibody, #ab15348, Abcam, Berlin, Germany),
TMPRSS2 (1:1000 dilution, Recombinant Anti-TMPRSS2 antibody [EPR3861], #ab92323, Abcam),
and GAPDH (1:1000 dilution, Anti-G3PDH Human Polyclonal Antibody, #2275-PC-100, Trevigen,
Wiesbaden, Germany). Protein bands were visualized by laser-induced fluorescence using an infrared
scanner for protein quantification (Odyssey, Li-Cor Biosciences, Bad Homburg, Germany).
2.10. Sample Preparation for LC–MS
Preparation of samples was performed as previously described [24] and labeled with TMTpro
multiplexing reagents.
2.11. Targeted Analysis by SPS–MS3
Mass spectrometry data were acquired in centroid mode on an Orbitrap Fusion Lumos mass
spectrometer hyphenated to an easy-nLC 1200 nano HPLC system using a nanoFlex ion source
(ThermoFisher Scientific) applying a spray voltage of 2.6 kV with the transfer tube heated to 300 ◦C and
a funnel RF of 30%. Internal mass calibration was enabled (lock mass 445.12003 m/z). Peptides were
separated on a self-made, 32 cm long, 75 µm ID fused-silica column, packed in house with 1.9 µm C18
particles (ReproSil-Pur, Dr. Maisch, Ammerbuch-Entringen, Germany) and heated to 50 ◦C using an
integrated column oven (Sonation, Biberach, Germany). The HPLC solvents consisted of 0.1% formic
acid in water (Buffer A) and 0.1% formic acid with 80% acetonitrile in water (Buffer B).
Dependent scans were performed on precursors matching a mass list of viral peptides modified
with TMTpro reagents and their charge states (mass tolerance was set to 5 ppm for matching precursors).
Peptides were eluted by a non-linear gradient from 5% to 40% B over 30 min, followed by a step-wise
increase to 95% B in 6 min, which was held for another 9 min. Full scan MS spectra (350–1500 m/z)
were acquired with a resolution of 120,000 at m/z 200, a maximum injection time of 100 ms, and an
automatic gain control (AGC) target value of 4 × 105. The 10 most intense precursors matching the
target list per full scan were selected for fragmentation (“Top 10”) and isolated with a quadrupole
isolation window of 0.4 Th. MS2 scans were performed in the Orbitrap using a maximum injection
time of 300 ms, an AGC target value of 1.5 × 104, and fragmented using HCD with a normalized
collision energy (NCE) of 35% and a fixed first mass of 110 m/z. Repeated sequencing of already
acquired precursors was limited by setting a dynamic exclusion of 20 s and 10 ppm and advanced
peak determination was deactivated.
2.12. Data Analysis
RAW data was processed with Proteome Discoverer 2.4 software. HCD-fragmented spectra were
searched against a SARS-CoV-2 proteome FASTA file (UniProt pre-realease) by SequestHT and the
false discovery rate (FDR) was calculated using a target/decoy-based approach. TMTpro reporter
abundances were extracted and used for plotting and statistical analysis.
2.13. Data Availability
The mass spectrometry proteomics data were deposited to the ProteomeXchange Consortium via
the PRIDE [25] partner repository with the dataset identifier PXD019950.
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3. Results
3.1. The Protease Inhibitor Aprotinin Exerts Superior Anti-SARS-CoV-2 Activity Relative to the Endogenous
Protease Inhibitor SERPINA1/alpha-1 Antitrypsin
We compared the anti-SARS-CoV-2 activity of aprotinin [15,26] and SERPINA1/alpha-1 antitrypsin,
an endogenous protease inhibitor that is available as a pharmaceutical preparation for the treatment
of alpha-1 antitrypsin deficiency [27], against three different SARS-CoV-2 isolates from two lineages
(L: SARS-CoV-2/FFM1 and SARS-CoV-2/FFM2; GR: SARS-CoV-2/FFM6) [18]. SARS-CoV-2/FFM1 and
SARS-CoV-2/FFM2 were isolated from patients in Hubei province in China, while SARS-CoV/FFM6
was derived from an Italian patient [18].
The aprotinin concentrations that inhibited the formation of cytopathogenic effects (CPEs)
by 50% (IC50) in SARS-CoV-2-infected Caco2 cells ranged from 0.81 µM (SARS-CoV-2/FFM2) to
1.03 µM (SARS-CoV-2/FFM1) across the three tested SARS-CoV-2 isolates, whereas SERPINA1/alpha-1
antitrypsin did not show significant antiviral effects in the tested concentrations up to 20 µM (Figure 1A).
Similar effects were observed by cell staining for SARS-CoV-2 S protein (Figure 1B and Figure S1, Table 1).
Quantification of genomic SARS-CoV-2 RNA using qPCR confirmed that aprotinin inhibits SARS-CoV-2
replication (Figure 1C). Aprotinin (20 µM) reduced the genomic RNA levels of SARS-CoV-2/FFM1 by
900-fold, those of SARS-CoV-2/FFM2 by 237-fold, and those of SARS-CoV-2/FFM6 by 584-fold.
Figure 1. Cont.
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Figure 1. Anti-severe acute respiratory syndrome virus 2 (SARS-CoV-2) effects of aprotinin and
SERPINA1/alpha-1 antitrypsin. (A) Concentration-dependent effects of aprotinin and SERPINA1/alpha-1
antitrypsin on SARS-CoV-2-induced cytopathogenic effect (CPE) formation determined 48 h
post-infection in Caco2 cells infected at a multiplicity of infection (MOI) of 0.01 with the three different
SARS-CoV-2 isolates. The viability of the Caco2 cells was 84.3 ± 2.7% relative to the untreated control in
the presence of 20 µM of aprotinin. (B) Immunostaining for the SARS-CoV-2 S protein in aprotinin- and
SERPINA1/alpha-1 antitrypsin-treated Caco2 cells infected at an MOI of 0.01 with the three different
SARS-CoV-2 isolates as determined 48 h post-infection. The protease inhibitors were tested at four
concentrations in 1:4 dilution steps ranging from 20 to 0.3125 µM. A quantification is provided in
Figure S1. (C) Copy numbers of genomic RNA in Caco2 cells infected with different SARS-CoV-2
isolates (MOI of 0.01) in response to treatment with aprotinin or SERPINA1/alpha-1 antitrypsin as
determined 48 h post-infection. FFM1, 1/Human/2020/Frankfurt; FFM2, 2/Human/2020/Frankfurt;
FFM6, 6/Human/2020/Frankfurt.
Table 1. Aprotinin concentrations that reduce SARS-CoV-2-induced cytopathogenic effect (CPE)
formation, SARS-CoV-2 spike (S) levels, and SARS-CoV-2-induced caspase 3/7 activation by 50% (IC50)
as determined in Caco2 cells infected with different SARS-CoV-2 isolates (MOI of 0.01) 48 h post-infection.
IC50 (µM)
FFM1 FFM2 FFM6
CPE formation 1.03 ± 0.07 0.81 ± 0.07 0.92 ± 0.03
S levels 0.79 ± 0.15 1.04 ± 0.21 1.65 ± 0.30
Caspase 3/7 activation 0.41 ± 0.25 0.32 ± 0.09 0.73 ± 0.40
Both aprotinin and SERPINA1/alpha-1 antitrypsin are trypsin inhibitors [26,28]. To verify the
integrity of the used protease inhibitor samples, we tested their capacity to antagonize trypsin and
enable Caco2 and A549 cell adhesion. The results confirmed that both protease inhibitors are active
(Figure S2). Taken together, these findings indicate differences in the protease inhibitor spectrum of
aprotinin and SERPINA1/alpha-1 antitrypsin that result in different effects on SARS-CoV-2 replication.
3.2. Quantification of the Antiviral Effects of Aprotinin by Measuring SARS-CoV-2-Induced Caspase 3/7
Activation
Different viruses, including SARS-CoV-2, have been shown to induce caspase 3 activation [29–32],
and virus-induced caspase 3 activation has been used as read-out in assays that quantify the antiviral
effects of drug candidates [31]. Hence, we used the Caspase-Glo® 3/7 Assay (Promega) as an additional
quantitative method to determine the anti-SARS-CoV-2 activity of aprotinin. The results confirmed
those obtained by CPE formation and S expression resulting in similar IC50 values (Figure 2, Table 1).
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Figure 2. Effects of aprotinin on SARS-CoV-2-induced caspase 3/7 activation. Caspase 3/7 activity was
determined in Caco2 cells infected with different SARS-CoV-2 isolates (MOI of 0.01) 48 h post-infection.
3.3. Aprotinin Inhibits Virus Entry
Protease inhibitors were suggested to interfere with SARS-CoV-2 replication predominantly as
entry inhibitors that prevent S cleavage and activation [15]. In agreement, aprotinin addition after a
one-hour adsorption period did not significantly interfere with SARS-CoV-2 replication in one round
of a replication assay, in which virus titers were determined 8 h post-infection with an MOI of 0.1
(Figure 3A). In contrast, remdesivir, which was anticipated to interfere with the replication of the viral
genome, inhibited SARS-CoV-2 replication when added post-infection (Figure 3A).
Figure 3. Anti-SARS-CoV-2 effects of aprotinin when administered post-infection. For post-infection
experiments, the cells were incubated with the virus for a one-hour adsorption period. Then, the cells
were washed three times in PBS prior to the addition of the drug. (A) The effects of aprotinin
and the RNA polymerase inhibitor remdesivir (a positive control drug that interferes with virus
replication after virus entry) on virus replication as determined by qPCR in SARS-CoV-2/FFM1 (MOI of
0.1)-infected Caco2 cells 8 h post-infection (after approximately one round of replication). * p < 0.05 as
determined by one-way ANOVA and Dunnett’s multiple comparison test. (B) The effects of aprotinin
on cytopathogenic effect (CPE) formation in SARS-CoV-2/FFM1 (MOI of 0.01)-infected Caco2 cells were
determined 48 h post-infection.
Cells 2020, 9, 2377 8 of 13
3.4. Aprotinin May Interfere with SARS-CoV-2-Mediated Downregulation of Host Cell Protease Inhibitors
Notably, aprotinin exerted similar anti-SARS-CoV-2 effects when added before or after infection
of Caco2 cells with a lower MOI (0.01) in a 48 h assay (Figure 3B). In this format, aprotinin probably
inhibits the later rounds of SARS-CoV-2 replication, but other mechanisms may also contribute.
Host cell protease inhibitors interfere with the activity of proteases such as TMPRSS2 [33,34] that
mediate SARS-CoV-2 cell entry by cleaving and activating the viral S protein [9,11,12]. An analysis of
the effect of SARS-CoV-2 infection on host cell protease inhibitors using proteomics data from
SARS-CoV-2-infected Caco2 cells [35] showed that the endogenous protease inhibitors SPINT1
(Kunitz-type protease inhibitor 1), SPINT2 (Kunitz-type protease inhibitor 2), and SERPINA1
(alpha-1-antitrypsin) are present at lower levels in SARS-CoV-2-infected cells than in non-infected
control cells 24 h post-infection (Figure 4A). Translatome data from the same dataset [35] indicated
that the translation of SERPINA1 and SPINT2 (but not that of SPINT1) is also reduced in
SARS-CoV-2-infected cells (Figure 4B). Hence, SARS-CoV-2 infection results in the downregulation of
endogenous protease inhibitors, which may support SARS-CoV-2 replication. Thus, compensation for
downregulated endogenous protease inhibitors may contribute to the antiviral effects of aprotinin.
Figure 4. Regulation of host cell protease inhibitors in SARS-CoV-2-infected cells. (A) Total protein
levels based on a publicly available proteomics dataset [35], indicating cellular levels of endogenous
protease inhibitors in SARS-CoV-2 (MOI of 1)-infected Caco2 cells 2 h and 24 h post-infection. Data were
normalized using summed intensity normalization for sample loading, followed by internal reference
scaling and trimmed mean of M normalization. * p-values as determined using a two-sided Student’s
t-test. (B) Mean protein translation of endogenous protease inhibitors in arbitrary units (AU) (normalized
and corrected summed peptide spectrum matches (PSMs) were averaged) in SARS-CoV-2 (MOI of
1)-infected Caco2 cells 2 h and 24 h post-infection based on a publicly available translatome dataset [35].
* p-values as determined using a two-sided Student’s t-test.
3.5. Aprotinin Exerts Anti-SARS-CoV-2 Activity in Air–Liquid Interface (ALI) Cultures from Primary
Bronchial Epithelial Cells
We also investigated the effects of aprotinin in SARS-CoV-2-infected air–liquid interface (ALI)
cultures from primary bronchial epithelial cells. A targeted proteomics assay demonstrated that
aprotinin 20 µM suppressed the expression of the SARS-CoV-2 proteins N (nucleocapsid protein) and
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M (membrane protein) in SARS-CoV-2-infected ALI cultures (Figure 5A, Table S1). The results for N
were confirmed by Western blots in the ALI cultures infected with SARS-CoV-2/FFM7 (Figure 5B).
SARS-CoV-2/FFM7 (G lineage) is an alternative isolate derived from a patient from Israel [18].
Aprotinin also suppressed SARS-CoV-2 S expression in SARS-CoV-2/FFM7-infected Calu-3 lung
adenocarcinoma cells (Figure S3).
Figure 5. Antiviral effects of aprotinin in SARS-CoV-2-infected air–liquid interface (ALI) cultures from
primary bronchial epithelial cells. (A) Abundance of the SARS-CoV-2 proteins N (nucleocapsid) and M
(membrane) in primary bronchial epithelial cell ALI cultures infected with SARS-CoV-2/FFM1 (MOI of
1) in the presence or absence of aprotinin (20 µM) as determined 5 days post-infection by multiplexed
mass spectrometry analysis using acquisition targeting of previously identified viral peptides modified
with TMTpro. The detailed data are presented in Table S1. (B) Western blots indicating cellular
SARS-CoV-2 N and TMPRSS2 levels in primary bronchial epithelial cell ALI cultures infected with
SARS-CoV-2/7/Human/2020/Frankfurt (FFM7) (MOI of 1) in the presence or absence of aprotinin as
detected 5 days post infection. GAPDH was served as the loading control. Uncropped Western blots
are shown in Figure S4.
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4. Discussion
Herein, we showed that aprotinin inhibits SARS-CoV-2 replication predominantly as
an entry inhibitor, probably via interfering with SARS-CoV-2 S activation by TMPRSS2.
Notably, SERPINA1/alpha-1 antitrypsin, which is available as a pharmaceutical preparation for the
treatment of alpha-1 antitrypsin deficiency [27], did not inhibit SARS-CoV-2 replication in the same
concentration range. Further investigations will have to elucidate the differences between aprotinin
and SERPINA1/alpha-1 antitrypsin that are responsible for the discrepancy in anti-SARS-CoV-2 activity.
Notably, SERPINA1/alpha-1 antitrypsin was shown to inhibit TMPRSS2 in an enzymatic assay and
is suggested as an antiviral treatment for COVID-19 [36]. A clinical trial testing SERPINA1/alpha-1
antitrypsin for the treatment of COVID-19 has recently been started (ClinicalTrials.gov Identifier:
NCT04385836). Based on our data, however, SERPINA1/alpha-1 antitrypsin is not expected to exert
direct antiviral effects in COVID-19 patients. Our findings also indicate that antiviral therapy candidates
should be tested for their effects on complete replication-competent viruses in permissive cells.
Aprotinin exerted anti-SARS-CoV-2 effects in three cell culture models (Caco2, Calu-3,
and air–liquid interface cultures from primary bronchial epithelial cells) and against three SARS-CoV-2
strains (FFM1, FFM2, FFM6, and FFM7). Notably, another study became available during the revision
of our manuscript that detected anti-SARS-CoV-2 activity of aprotinin in Calu-3 cells [37]. Our findings
are also in agreement with studies that reported other TMPRSS2 inhibitors to inhibit SARS-CoV-2 entry
and replication [11–13]. In addition, furin has been shown to cleave and activate SARS-CoV-2 S and
furin inhibitors have been demonstrated to exert anti-SARS-CoV-2 effects [38].
Endogenous protease inhibitors may interfere with the activation of virus surface proteins such
as S by host cell proteases [9,11,12,33,34]. Our analysis of proteomics and translatome data from
SARS-CoV-2-infected Caco2 cells [35] revealed a downregulation of endogenous protease inhibitors in
response to SARS-CoV-2 infection, which may contribute to efficient SARS-CoV-2 replication. In addition
to entry inhibition, compensation for downregulated endogenous proteases may, hence, further contribute
to the antiviral activity of aprotinin during later rounds of SARS-CoV-2 replication.
The clinical potency of aprotinin is typically measured in kallikrein inhibitor units (KIUs) [14,39].
Therapeutic aprotinin plasma levels were described to reach 147± 61 KIU/mL after the administration of
1,000,000 KIU [39]. Moreover, an aerosol preparation of aprotinin, which is likely to result in increased
local aprotinin concentrations in the lung, is approved for the treatment of influenza in Russia [14].
The aprotinin IC50 values for SARS-CoV-2-induced CPE formation, S expression, and apoptosis
induction ranged from 0.32 to 1.65 µM, which is equivalent to 4.0 KIU and 20.6 KIU, respectively.
Hence, aprotinin interferes with SARS-CoV-2 infection in therapeutically achievable concentrations.
Aprotinin exerts pro- and antithrombotic effects by balancing fibrinolysis and thrombus formation
and is approved for the prevention of blood loss during surgery. It interferes with the fibrinolysis
of established thrombi by plasmin, but also inhibits contact-activated thrombus formation in the
blood stream [26,40–43]. Late-stage, severe COVID-19 disease has been associated with disseminated
intravascular coagulation and thrombosis (COVID-19-related coagulopathy) [44]. Based on the available
data, it is not clear whether aprotinin may exert pro- or antithrombotic effects in patients suffering
from COVID-19-related coagulopathy. Thus, aprotinin would have to be considered with care for
such patients.
However, antiviral treatment may anyway be of limited impact in late-stage COVID-19 disease,
during which, damage is anticipated to be largely caused by immunopathology and not by virus
replication [42,45,46]. Hence, the main potential of antiviral drugs may lie in the early treatment of
COVID-19 patients to suppress virus replication and, through this, to prevent COVID-19 progression
into a severe, life-threatening disease. Local aprotinin therapy of the airways and the lungs using
an aerosol, which is clinically approved in Russia and has been reported to be very well tolerated in
influenza patients [14], may have particular potential as such an antiviral treatment for early stage
COVID-19 disease. Notably, aprotinin may additionally prevent the very early stages of lung injury by
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inhibition of matrix metalloproteinases and, in turn, of the cytokine storm that eventually results in
severe, systemic COVID-19 disease [26].
5. Conclusions
In conclusion, therapeutic aprotinin concentrations inhibit SARS-CoV-2 replication as entry
inhibitors and by compensating for downregulated cellular protease inhibitors during later replication
cycles. Local treatment of the respiratory tract using an aprotinin aerosol, which is approved in
Russia for the treatment of influenza [14], may be a particularly promising strategy to suppress virus
replication and lung injury early and to prevent COVID-19 progression into a severe, systemic disease.
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